Patent 10308943 was granted and assigned to Vitrisa Therapeutics on June, 2019 by the United States Patent and Trademark Office.
Provided herein are compositions and methods for the treatment of retinal diseases. The compositions and methods include a therapeutic agent conjugated to a vitreous component binding moiety. The vitreous component binding moiety may be an aptamer or a small molecule that binds to a structural component of the vitreous humor (e.g., hyaluronic acid, collagen or vitronectin).